D. Boral Capital Reaffirms Buy Rating for FibroBiologics (NASDAQ:FBLG)

D. Boral Capital reissued their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $16.00 target price on the stock.

Several other analysts also recently weighed in on FBLG. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of FibroBiologics in a research report on Thursday. Rodman & Renshaw began coverage on FibroBiologics in a research report on Thursday, December 12th. They set a “buy” rating and a $12.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Stock Down 4.7 %

NASDAQ FBLG opened at $1.23 on Thursday. The company has a fifty day moving average of $1.93 and a two-hundred day moving average of $2.43. FibroBiologics has a 52 week low of $1.06 and a 52 week high of $15.50.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in FBLG. Symphony Financial Ltd. Co. acquired a new position in FibroBiologics in the 3rd quarter valued at $76,000. Charles Schwab Investment Management Inc. raised its stake in FibroBiologics by 5.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock valued at $215,000 after purchasing an additional 3,451 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in FibroBiologics in the 3rd quarter valued at $32,000. State Street Corp raised its stake in FibroBiologics by 26.5% in the 3rd quarter. State Street Corp now owns 475,837 shares of the company’s stock valued at $1,470,000 after purchasing an additional 99,789 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in FibroBiologics in the 3rd quarter valued at $37,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.